Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GALR1 | P47211 | 7/20 | 0.44 |
| ▸ | BCL6 | P41182 | 1/20 | 0.44 |
| ▸ | CTSL | P07711 | 1/20 | 0.40 |
| ▸ | CTSS | P25774 | 1/20 | 0.40 |
| ▸ | CTSK | P43235 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | GALR2 | O43603 | 7/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4829617 | 1.00 | GALR1 (0.44) | GALR1BCL6CTSLCTSSCTSK | |
| SCHEMBL4832646 | 1.00 | GALR1 (0.44) | GALR1BCL6CTSLCTSSCTSK | |
| SCHEMBL6013788 | 1.00 | GALR1 (0.44) | GALR1BCL6CTSLCTSSCTSK | |
| SCHEMBL4838952 | 1.00 | GALR1 (0.44) | GALR1BCL6CTSLCTSSCTSK | |
| Hydrochloric Acid SCHEMBL4838895 | 0.99 | GALR1 (0.44) | GALR1BCL6CTSLCTSSCTSK | |
| SCHEMBL4832251 | 0.97 | GALR1 (0.42) | GALR1BCL6CTSLCTSSCTSK | |
| SCHEMBL5555460 | 0.94 | CTSL (0.41) | GALR1BCL6CTSLCTSSCTSK | |
| SCHEMBL4832502 | 0.93 | GALR1 (0.45) | GALR1BCL6MAPK1GALR2 | |
| SCHEMBL5554791 | 0.93 | IDH2 (0.44) | GALR1BCL6MAPK1GALR2 | |
| SCHEMBL5550320 | 0.92 | BCL6 (0.40) | GALR1BCL6CTSLCTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7132423-B2 | Methods and compositions of novel triazine compounds | REDDY US THERAPEUTICS, INC. (US) | 2006-11-07 | — | — | US | disclosed |
| US-20060172984-A1 | Methods and compositions of novel triazine compounds | DR. REDDY'S LABORATORIES LTD. (IN) | 2006-08-03 | — | — | US | disclosed |
| US-20040224950-A1 | Methods and compositions of novel triazine compounds | DR. REDDY'S LABORATORIES LTD. (IN) | 2004-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040224950-A1 | Methods and compositions of novel triazine compounds | AREG, TGFB1, PTGIS | GALR1 961/4885BCL6 2097/4885CTSL 2846/4885 |
| US-20060172984-A1 | Methods and compositions of novel triazine compounds | AREG, TGFB1, PTGIS | GALR1 961/4885BCL6 2097/4885CTSL 2846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.